Found 67 articles for: "Alopecia"
Patients With Lichen Planopilaris Are at Increased Risk of Skin Cancer
May 2026 | Volume 25 | Issue 5 | Features | 479 | Copyright © May 2026
Treatment or Trigger? The Use of Biologic Therapy for Alopecia Areata
May 2026 | Volume 25 | Issue 5 | Features | 489 | Copyright © May 2026
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MorePersistent Alopecic Patches Following Dutasteride Mesotherapy for Female Androgenetic Alopecia: A Case Series
March 2026 | Volume 25 | Issue 3 | Original Article | 951 | Copyright © March 2026
Background: Androgenetic alopecia (AGA) is the most common cause of hair loss. To minimize systemic adverse effects of 5-alpha-reductase inhibitors, dutasteride mesotherapy has g...
Read MoreUpdates on Therapeutic Approaches for Management of Androgenetic Alopecia: A Review
March 2026 | Volume 25 | Issue 3 | Original Article | 240 | Copyright © March 2026
Androgenetic alopecia (AGA) is a common, progressive form of nonscarring hair loss, affecting both men and women. Its pathogenesis is largely driven by androgenic factors, including elevated dihy...
Read MoreFrom Bald to Bold: Reversal of Alopecia Totalis in an Adolescent Using Dupilumab Monotherapy
March 2026 | Volume 25 | Issue 3 | Case Reports | 273 | Copyright © March 2026
Introduction: Alopecia areata (AA) is an autoimmune condition marked by non-scarring, patchy hair loss of the scalp which progresses in <10% of cases to alopecia totalis (AT),...
Read MoreBaricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Patient Perspectives and Attitudes Toward the Diagnostic Process for Central Centrifugal Cicatricial Alopecia
March 2026 | Volume 25 | Issue 3 | Features | 282 | Copyright © March 2026
A Decade of Hair Prosthetic Injuries: A Review of United States Emergency Department Cases (2013-2022)
March 2026 | Volume 25 | Issue 3 | Features | 277 | Copyright © March 2026
Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics
March 2026 | Volume 25 | Issue 3 | Case Reports | 275 | Copyright © March 2026
Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disorder of the scalp that manifests as inflamed nodules and abscesses, with subsequent patchy, scarring hair loss. While its ex...
Read MoreMicroneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia
October 2025 | Volume 24 | Issue 10 | Editorials | e59 | Copyright © October 2025
Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia: An Open-Label Pilot Study
September 2025 | Volume 24 | Issue 9 | Original Article | 891 | Copyright © September 2025
Background: Central centrifugal cicatricial alopecia (CCCA) is a scarring alopecia primarily affecting Black women. To date, there are no standardized treatment regimens or appro...
Read MoreHair Transplantation in Women
September 2025 | Volume 24 | Issue 9 | Original Article | 851 | Copyright © September 2025
Background: Hair transplantation is a widely used treatment for androgenetic alopecia (AGA) and other hair loss conditions, with increasing demand from women in recent years.Read MorePost-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management
September 2025 | Volume 24 | Issue 9 | Case Reports | 938 | Copyright © September 2025
Background: Alopecia universalis (AU) is the most severe form of alopecia areata (AA), characterized by complete scalp and body hair loss. While post-COVID-19 hair loss is often ...
Read MoreAlopecia Areata in Skin of Color: Trichoscopic Analysis in Black/African American Patients
July 2025 | Volume 24 | Issue 7 | Features | 708 | Copyright © July 2025
Importance: Alopecia areata (AA) has a higher prevalence in populations with skin of color, yet the trichoscopic features in this population remain underexplored.Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions
July 2025 | Volume 24 | Issue 7 | Original Article | 659 | Copyright © July 2025
Female hair loss affects over 50% of postmenopausal women, with up to 40% of healthy women experiencing frontal/parietal hair loss, often beginning around reproductive age. Androgenetic alopecia ...
Read MoreA Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies
April 2025 | Volume 24 | Issue 4 | Features | 413 | Copyright © April 2025
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack o...
Read MoreAlopecia Universalis: Never Give Up?
March 2025 | Volume 24 | Issue 3 | Case Reports | 316 | Copyright © March 2025
Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medicati...
Read MoreConcurrent Lichen Planopilaris and Female Androgenic Alopecia in Skin of Color: A Case Series
March 2025 | Volume 24 | Issue 3 | Case Reports | 320 | Copyright © March 2025
Background: Trichoscopy findings can differ in the skin of color requiring a dedicated approach with adequate examination in order to ensure proper diagnosis and treatment. This ...
Read MoreAlopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes
March 2025 | Volume 24 | Issue 3 | Original Article | 255 | Copyright © March 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
